Sugi Predict

Sugi Predict / Compounds / SCHEMBL6326249

SCHEMBL6326249

SCHEMBL6326249

CNC(=O)[C@@H](Cc1ccccc1)N(C)C(=O)[C@@H](Cc1csc2ccccc12)NCC(=O)COCC(C)(C)N

nearest known ligand 0.41

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
▸ CTSL P07711 1/20 0.41
▸ CTSS P25774 1/20 0.41
▸ CTSK P43235 1/20 0.41
▸ MMP2 P08253 2/20 0.39
▸ MMP9 P14780 2/20 0.39
▸ MMP8 P22894 2/20 0.39
▸ TACR1 P25103 1/20 0.38
▸ OPRM1 P35372 2/20 0.35
▸ OPRD1 P41143 2/20 0.35
▸ OPRK1 P41145 2/20 0.35
▸ KLKB1 P03952 4/20 0.35
▸ KLK1 P06870 3/20 0.35
▸ POLB P06746 1/20 0.34
▸ CASP1 P29466 1/20 0.33
▸ PYGL P06737 1/20 0.33
▸ F10 P00742 1/20 0.32
▸ TP53 P04637 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6324008 0.85 CTSL (0.39) CTSLCTSSCTSKMMP2MMP9
SCHEMBL6319054 0.81 MMP2 (0.48) CTSLCTSSCTSKMMP2MMP9
SCHEMBL6317894 0.81 MMP2 (0.48) CTSLCTSSCTSKMMP2MMP9
SCHEMBL6318207 0.79 KLKB1 (0.39) CTSLCTSSCTSKMMP2MMP9
SCHEMBL6325536 0.78 MC4R (0.40) MMP9MMP8
SCHEMBL6323968 0.76 TACR1 (0.37) CTSLCTSSCTSKMMP2MMP9
SCHEMBL6325830 0.76 CTSL (0.48) CTSLCTSSCTSKMMP2MMP9
SCHEMBL6319686 0.76 MMP2 (0.44) CTSLCTSSCTSKMMP2MMP9
SCHEMBL6319248 0.76 MMP2 (0.36) CTSLCTSSCTSKMMP2MMP9
SCHEMBL6320214 0.75 HRH4 (0.37) CTSSCTSKMMP2MMP9MMP8

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6939880-B2 Compounds with growth hormone releasing properties NOVO NORDISK A/S (DK) 2005-09-06 — — US disclosed
US-6555570-B2 Growth hormone secretagogous with improved bioavailability NOVO NORDISK A/S (DE) 2003-04-29 — — US disclosed
US-20030055261-A1 Compounds with growth hormone releasing properties HELSINN THERAPEUTICS (U.S.), INC. 2003-03-20 — — US disclosed
US-20030040483-A1 Compounds with growth hormone releasing properties HELSINN THERAPEUTICS (U.S.), INC. 2003-02-27 — — US disclosed
US-6127391-A A PEPTIDE MIMETIC COMPOUND FOR STIMULATING THE RELEASE OF GROWTH HORMONE FROM THE PITUITARY NOVO NORDISK A/S (DK) 2000-10-03 — — US disclosed
EP-0869974-A1 COMPOUNDS WITH GROWTH HORMONE RELEASING PROPERTIES NOVO NORDISK A/S (DK) 1998-10-14 — — EP disclosed
WO-1997023508-A1 COMPOUNDS WITH GROWTH HORMONE RELEASING PROPERTIES NOVO NORDISK A/S (DK) 1997-07-03 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030055261-A1 Compounds with growth hormone releasing properties GHRHR, GHSR, IGFBP1 CTSL 1294/4885CTSS 2319/4885CTSK 1324/4885
US-20030040483-A1 Compounds with growth hormone releasing properties GHRHR, GHSR, GRPR CTSL 1539/4885CTSS 2636/4885CTSK 1778/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.